Search Bar & Filters
Found 104 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.
Actively Recruiting
Researchers are evaluating MK-1045, an immunotherapy, for treating two types of non-Hodgkin lymphoma NHL follicular lymphoma FL, which grows slowly, and diffuse large B-cell lymphoma DLBCL, which grows quickly. NHL is a cancer of the lymphatic system causing swollen lymph nodes. The study aims to learn about the safety and tolerability of MK-1045 and whether it helps reduce or eliminate these lymphomas. Participants are randomly assigned to one of four groups receiving MK-1045 in different doses and methods intravenous IV infusion or subcutaneous SC injection. Treatment continues for up to approximately one year or until participants stop. The study includes phases 1b and 2 and involves optimizing doses and schedules, including longer dosing intervals and subcutaneous administration. During the study, participants will have regular assessments including monitoring for adverse events, response to treatment using the Lugano Response Criteria, and measuring drug levels in the body. Researchers will track safety up to about 49 months and monitor discontinuation due to side effects for up to 12 months. Tumor tissue samples and other laboratory tests will also be collected to understand treatment effects. The total participation can last several years with ongoing evaluations.
Actively Recruiting
Researchers are evaluating the combination of BNT324, a B7-H3 antibody-drug conjugate, with BNT327, a bispecific antibody targeting PD-L1 and VEGF, in adults with advanced or metastatic small cell lung cancer SCLC and non-small cell lung cancer NSCLC. This two-part Phase IbII trial aims to find safe dose levels, optimize dosing, and assess preliminary efficacy and safety in various lung cancer patient groups. Participants in Part 1 receive escalating doses of BNT324 with BNT327 to determine recommended dose levels. Part 2 compares these dose levels in randomized cohorts of treatment-naive NSCLC and relapsed SCLC patients, with additional cohorts receiving the optimal dose to further evaluate efficacy and safety. Treatments are given via intravenous infusion, and dosing is adjusted based on safety and response data. Throughout the study, participants undergo screening, treatment, safety follow-up, and long-term survival monitoring. Researchers assess dose-limiting toxicities, adverse events, objective response rates, disease control, progression-free survival, and overall survival. Treatment effects are evaluated up to 87 months, with close monitoring for side effects and treatment tolerability during and after therapy.
Actively Recruiting
Researchers are evaluating new treatments for follicular lymphoma FL, a type of cancer. This trial studies the combination of a new immunotherapy drug, MK-1045, with rituximab, a targeted therapy, compared to the usual treatment of rituximab combined with chemotherapy. The goal is to assess safety, tolerability, cancer response, and how long participants live without disease progression. Participants receive escalating doses of MK-1045 once weekly for up to about 12 months along with rituximab every 4 weeks for up to 6 months. In a comparison group, participants receive standard chemotherapy options chosen by their doctor plus rituximab for up to 4 to 6 months depending on the regimen. The study includes two parts a dose-finding phase and a randomized phase to compare treatments. During the study, participants undergo regular monitoring for side effects and treatment response over several years. Evaluations include imaging to measure cancer, laboratory tests, and questionnaires about quality of life. The main outcomes measured are adverse events, treatment discontinuation due to side effects, cancer remission rates, progression-free survival, and overall survival. Follow-up lasts up to around 5 years after treatment starts.
Actively Recruiting
Researchers are evaluating how the drug pelabresib affects the way other drugs are processed in the body in adults with advanced cancers who have no standard treatment options left. This study aims to understand the interactions between pelabresib and three specific drug combinations repaglinide with midazolam, and a combined oral contraceptive containing drospirenone and ethinyl estradiol. The trial is phase 1b and open-label, focusing on treatment effects in this patient population. The study has two parts. In Part 1, participants are assigned to one of two groups Arm A receives pelabresib with repaglinide and midazolam, and Arm B receives pelabresib with drospirenone and ethinyl estradiol. Pelabresib is given orally at 225 mg daily for 14 days followed by a 7-day break. Participants in Arm A are hospitalized for two nights around specific dosing days, while those in Arm B may be hospitalized for up to 10 nights in total during the dosing schedule. Part 2 allows participants who benefit clinically to continue pelabresib treatment in additional cycles until the study ends or other stopping criteria are met. Participants start with a screening visit and then receive their first dose after enrollment. They undergo pharmacokinetic blood sampling over 21-day cycles to measure drug levels and interactions. Safety is monitored through adverse event reporting, and participants have an End of Treatment visit within 7 days after stopping pelabresib. A 30-day safety follow-up monitors for side effects, and those with blood cancers have additional follow-up every 3 months to check for progression to acute leukemia. Total participation duration varies depending on treatment continuation and follow-up needs.
Actively Recruiting
Researchers are evaluating KK2223 in adults with relapsed or refractory peripheral T cell lymphoma PTCL or cutaneous T cell lymphoma CTCL. This Phase 1, multicenter, open-label, non-randomized study aims to understand the safety, tolerability, pharmacokinetics, and pharmacodynamics of KK2223 in these lymphoma subtypes. The study has two parts a dose-escalation phase and a backfill phase to further assess dosing and safety. Participants will receive KK2223 by intravenous infusion. In Part 1, the study uses a dose-escalation design to find the maximum tolerated dose by gradually increasing dose levels. Part 2 collects additional data at doses found to be tolerable in Part 1, with cohort sizes and dose levels based on earlier results. Enrollment priority may be given to participants in the dose-escalation phase. Throughout the study, participants will undergo regular assessments including safety monitoring for adverse events, blood tests to measure drug levels and immune response, and evaluations of anti-tumor activity. Researchers will monitor treatment effects and drug behavior over approximately 1.5 years. Participants must comply with study procedures and provide tumor tissue samples for evaluation. The study involves periodic visits and monitoring to assess outcomes like safety, drug concentration, and tumor response.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.
Actively Recruiting
Researchers are evaluating a personalized, stage-related, multimodal treatment approach for patients with rectal adenocarcinoma. The study focuses on organ preservation, especially in early-stage tumors, and prioritizes minimally invasive techniques like laparoscopic and robotic surgery to reduce the physical and psychological impact on patients. This phase II, single-center, interventional study aims to improve quality of life while managing rectal cancer effectively. Patients are divided into three groups based on tumor stage before treatment. Group 1 includes patients with early-stage tumors who may undergo local excision or endoscopic resection followed by experimental chemoradiotherapy and a Watch and Wait strategy if surgery is declined. Group 2 involves patients with cT2N0 tumors offered an alternative experimental chemoradiotherapy approach with restaging to decide on organ-sparing strategies or local excision. Group 3 patients with more advanced tumors receive standard chemoradiotherapy and may be considered for organ-sparing methods if they respond well. If organ-sparing is not possible, minimally invasive surgery is performed with nerve preservation and enhanced recovery protocols. Participants undergo thorough imaging and diagnostic assessments including pelvic MRI, CT scans, PET, endorectal ultrasound, and rectoscopy for accurate staging and restaging. The study monitors clinical and pathological responses, quality of life, bowel function, and long-term disease outcomes. Close surveillance follows organ-preserving treatments. The primary outcome is development of a scoring system to predict complete tumor response. Participants are followed for several years to assess survival, quality of life, and bowel function after different treatment approaches.
Actively Recruiting
Researchers are conducting a master protocol trial designed to efficiently study several different drugs for children and young adults with various types of cancer. This approach allows multiple clinical trials under one common research plan, with each trial focusing on specific cancers like desmoplastic small round cell tumor, synovial sarcoma, and Ewings sarcoma. New drug studies may be added over time as new treatments emerge. Participation depends on how long the treatment benefits last. The study evaluates combinations of drugs given in cycles, including intravenous and oral medicines such as ramucirumab, cyclophosphamide, vinorelbine, gemcitabine, docetaxel, abemaciclib, irinotecan, and temozolomide. Different treatment groups receive specific drug combinations tailored to the cancer type, with treatment cycles lasting 21 or 28 days depending on the regimen. Each group is randomized to receive either an experimental drug combination or an active comparator without any blinding. Participants will be involved from screening through treatment and monitored regularly. Researchers will assess how many participants are assigned to each specific intervention plan within the first four weeks and track treatment effects. Participants must have measurable or evaluable disease, adequate organ function, and meet performance status criteria. Female participants of childbearing potential undergo pregnancy testing and must use contraception during and after treatment. Safety, adherence, and side effects are carefully monitored throughout the study, which is expected to continue until 2027.
Actively Recruiting
Researchers are evaluating the plasma expression of miRNA 371a-3p miRNA 371 as a specific marker to detect the presence or absence of viable germ cell malignancy in male patients newly diagnosed with testicular germ cell tumors or those with a history of this cancer. This observational cohort study aims to understand how well miRNA 371 can indicate relapse risk in early-stage testicular seminoma and nonseminoma groups. The study is sponsored by Fondazione del Piemonte per lOncologia and focuses on measuring miRNA levels and relapse outcomes over 48 months. Patients are grouped based on their risk of relapse low risk 5-25% chance or moderate risk 26-50% chance. Those in the low-risk group will follow a low-intensity schedule involving biospecimen collection and imaging, while the moderate-risk group will have a higher intensity schedule including additional early imaging and classic cancer marker tests. The study observes these patients without administering any investigational treatments. Participants will undergo regular blood tests to measure miRNA 371 levels and classic tumor markers like beta-HCG, AFP, and LDH. Imaging and clinical evaluations will be done within 42 days before registration and monitored over the 48-month study period. Researchers will track relapse rates, relapse-free survival, and overall survival, collecting pathology reports and performance status data. Participants must provide informed consent and blood samples throughout the study duration.
1-10 of 104
1